Name | Ro 5126766 |
Synonyms | CS-1469 CH5126766 Ro 5126766 RO5126766(CH5126766) 3-{2-(methylaminosulfonyl)amino-3-fluoropyridin-4-ylmethyl}-4-methyl-7-(pyrimidin-2-yloxy)-2-oxo-2H-1-benzopyran Sulfamide, N-[3-fluoro-4-[[4-methyl-2-oxo-7-(2-pyrimidinyloxy)-2H-1-benzopyran-3-yl]methyl]-2-pyridinyl]-N'-methyl- 3-[[2-[(Methylaminosulfonyl)amino]-3-fluoropyridin-4-yl]methyl]-4-methyl-7-[(pyrimidin-2-yl)oxy]-2H-1-benzopyran-2-one RO5126766(CH5126766) 3-[[2-[(Methylaminosulfonyl)amino]-3-fluoropyridin-4-yl]methyl]-4-methyl-7-[(pyrimidin-2-yl)oxy]-2H-1-benzopyran-2-one |
CAS | 946128-88-7 |
Molecular Formula | C21H18FN5O5S |
Molar Mass | 471.46 |
Density | 1.495±0.06 g/cm3(Predicted) |
Boling Point | 690.8±65.0 °C(Predicted) |
Solubility | 10 mM in DMSO |
pKa | 6.60±0.50(Predicted) |
Storage Condition | -20℃ |
In vitro study | In HCT116 KRAS-mutant colorectal cancer cells, CH5126766 significantly reduced the levels of phospho-MEK and phospho-ERK. CH5126766 inhibits RAF kinase by binding to MEK1 and makes MEK a dominant negative inhibitor of RAF. In Raf or RAS-mutant cell lines SK-MEL-28,SK-MEL-2,MIAPaCa-2,SW480,HCT116, and PC3 cells, CH5126766 inhibited cell growth with IC50 of 65,28,40,46, and 277 nM. In two melanoma cell lines containing either BRAF V600E or NRAS mutations, RO5126766 induced G1 cell cycle arrest with CDK inhibitor p27 upregulation and cyclin D1 downregulation. |
In vivo study | In the HCT116 (G13D KRAS) mouse xenograft model, CH5126766 (25 mg/kg, p.o.) inhibition of ERK signaling output is more potent than standard MEK inhibitors, which induce MEK phosphorylation, and have potent anti-tumor activity. In HCT116 (K-ras) and COLO205 (B-raf) mutant xenografts, CH5126766 (0.3 mg/kg) caused a significant reduction in [18 μF] FDG uptake. RO5126766 also inhibited tumor growth in a SK-MEL-2 xenograft model. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.121 ml | 10.605 ml | 21.211 ml |
5 mM | 0.424 ml | 2.121 ml | 4.242 ml |
10 mM | 0.212 ml | 1.061 ml | 2.121 ml |
5 mM | 0.042 ml | 0.212 ml | 0.424 ml |